BBOX1 promotes triple-negative breast cancer progression by controlling IP3R3 stability

Research output: Contribution to journalArticlepeer-review

3 Scopus citations

Abstract

Limited therapeutic options impede the clinical outcome of triple-negative breast cancer (TNBC). Our recent study uncovered a novel signaling pathway implicating gamma-butyrobetaine hydroxylase 1 (BBOX1) in the control of cell growth in TNBC, via inositol 1, 4, 5-trisphosphate receptor type 3 (IP3R3) mediated calcium signaling which is essential for cellular energy metabolism.

Original languageEnglish (US)
Article number1813526
JournalMolecular and Cellular Oncology
Volume7
Issue number6
DOIs
StatePublished - Nov 1 2020

Keywords

  • 2-OG dependent enzyme
  • TNBC
  • therapeutic target

ASJC Scopus subject areas

  • Molecular Medicine
  • Cancer Research

Fingerprint

Dive into the research topics of 'BBOX1 promotes triple-negative breast cancer progression by controlling IP3R3 stability'. Together they form a unique fingerprint.

Cite this